Cytodyn Inc (CYDY)

[JPG77]

According to this PR from Caracciolo when he announced his acquisition of ProstaGene and adding Pestell to the Board of Directors (we all know how that turned out), Caracciolo also announced "The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication." This gives the appearance that Tony was escorted out the door and why Tony's loyalist are trying desperately to make it look like it's NP's fault. And talk about wasted shares and massive dilution? It's sad that the failed 13D gang of miscreants are still blaming Tony's missteps on NP.

https://investorshub.advfn.com/secure/post_reply.aspx?message_id=166577310

Nader PURPOSELY set the HIV BLA back 18 to 24 months

"Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” said Anthony D. Caracciolo, CytoDyn’s Chairman. “We are privileged to have Richard join CytoDyn to expand our executive and scientific team, and we enthusiastically welcome him as the newest member of our board of directors.

Under the terms of the definitive agreement, CytoDyn acquired substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. The aggregate transaction consideration consisted of 27,000,000 shares of CytoDyn common stock. One-fifth of the stock consideration is being held back for distribution over an 18-month escrow period, to the extent not needed to satisfy indemnity claims. Approximately one-half of the stock consideration otherwise distributable to Dr. Pestell (approximately 8.3 million shares) is restricted and subject to vesting and forfeiture upon certain events over a three-year period. The total transaction value, based on the $0.5696 closing share price for CytoDyn common stock on November 15, 2018, was approximately $15.4 million."